Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

Taro Kishi,1 Kazuto Oya,1 Yuki Matsui,1,2 Ikuo Nomura,1 Kenji Sakuma,1 Makoto Okuya,1 Yuki Matsuda,3 ,Kiyoshi Fujita,4 Toshihiko Funahashi,2 Reiji Yoshimura,5 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan; 2Department of Psychiat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kishi T, Oya K, Matsui Y, Nomura I, Sakuma K, Okuya M, Matsuda Y, Fujita K, Funahashi T, Yoshimura R, Iwata N
Format: article
Language:EN
Published: Dove Medical Press 2018
Subjects:
schizophrenia
brexpiprazole 2mg/day
brexpiprazole 4mg/day
efficacy
safety
systematic review and meta-analysis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Online Access:https://doaj.org/article/9dc82aa5f11f42a6af99f9d13f91ddac
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/9dc82aa5f11f42a6af99f9d13f91ddac

Similar Items